Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Myeloid Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Hematopoietic and Lymphoid Cell Neoplasm
Myeloid Neoplasm

Cancer Family

Myeloid Neoplasm

CI-CAN-00000279Explore in graph →

HematologicNon-malignant1,102 active trials29 approved drugs653 evidence items

NCIt: C9290
OncoTree: MNM
DOID: 0070004

Overview
Statistics
Survival
Genomics22
Variants & evidence653
Drugs61
Trials4789
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (234)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 201–225 of 234 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
· Blood · 2006 · PMID 16434489 · validated civic_curation pubmed
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
· Oncotarget · 2017 · PMID 28077790 · validated civic_curation pubmed
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
· ACS Med Chem Lett · 2018 · PMID 29670690 · validated civic_curation pubmed
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.
· Cancer Cell · 2008 · PMID 18394554 · validated civic_curation pubmed
FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
· Blood · 2005 · PMID 15626738 · validated civic_curation pubmed
Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1.
· Blood · 2011 · PMID 21719597 · validated civic_curation pubmed
Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study.
· PLoS One · 2013 · PMID 24236021 · validated

Showing 201–225 of 234 publications

← Previous
1
…
8
9
10
Next →

civic_curation

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.

· Nat Chem Biol · 2015 · PMID 26436839 · validated civic_curation pubmed

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

· Blood · 2013 · PMID 23430109 · validated civic_curation pubmed

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.

· Cancer Res · 2009 · PMID 19318574 · validated civic_curation pubmed

Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.

· Nat Chem Biol · 2015 · PMID 26167872 · validated civic_curation pubmed

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.

· Exp Hematol · 2014 · PMID 24407160 · validated civic_curation pubmed

Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.

· Exp Hematol · 2014 · PMID 24333121 · validated civic_curation pubmed

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.

· Leuk Res · 2008 · PMID 18191450 · validated civic_curation pubmed

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.

· Blood · 2006 · PMID 16772610 · validated civic_curation pubmed

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.

· Blood · 2004 · PMID 15256420 · validated civic_curation pubmed

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.

· Blood · 2004 · PMID 15304385 · validated civic_curation pubmed

AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells.

· Leukemia · 2007 · PMID 17330097 · validated civic_curation pubmed

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.

· Proc Natl Acad Sci U S A · 2005 · PMID 15705718 · validated civic_curation pubmed

Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia.

· Mol Cancer Ther · 2018 · PMID 29237803 · validated civic_curation pubmed

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

· Blood · 2004 · PMID 15178581 · validated civic_curation pubmed

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.

· Blood · 2017 · PMID 27908881 · validated civic_curation pubmed

Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.

· Nat Commun · 2019 · PMID 31784538 · validated civic_curation pubmed

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

· Cancer Cell · 2007 · PMID 18068628 · validated civic_curation pubmed

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

· Leukemia · 2016 · PMID 26582647 · validated civic_curation pubmed